Insuman Comb 50 Solostar (Insulin Human)

• Insuman Comb 50 Solostar, a human insulin, is used in the management of diabetes mellitus to regulate blood glucose.
• Type 1 diabetes mellitus: provides basal insulin to maintain fasting glucose levels.
• Type 2 diabetes mellitus: supplements endogenous insulin to improve postprandial control.
• Hyperglycemia (hospitalized patients): enables rapid correction of elevated blood glucose under medical supervision.

• Insulin Human binds to insulin receptors on muscle, adipose and hepatic cells, activating the receptor's tyrosine kinase activity. This triggers intracellular signaling pathways that promote glucose uptake, glycogen synthesis, and lipogenesis while suppressing hepatic gluconeogenesis, thereby lowering circulating glucose concentrations.

Common Side Effects

• Hypoglycemia: low blood sugar episodes, especially if meals are missed or dosing is excessive.
• Injection‑site reactions: redness, swelling, or itching at the injection site.
• Weight gain: increased caloric storage due to improved glucose utilization.
• Lipodystrophy: localized fat accumulation or loss with repeated injections.
• Edema: mild fluid retention in extremities.

Serious or Rare Side Effects

• Severe hypoglycemia: neurological impairment requiring immediate assistance.
• Anaphylactic reaction: acute allergic response with rash, bronchospasm, or hypotension.
• Insulin antibodies: may alter insulin action and cause unpredictable glucose control.
• Hypokalemia: low potassium levels in rare cases of massive insulin administration.
• Necrotizing fasciitis: extremely rare soft‑tissue infection at injection sites.

Before initiating therapy, assess baseline blood glucose and renal function.

• Monitor glucose: adjust dose based on frequent self‑monitoring and clinical response.
• Adjust during illness: reduce or suspend insulin if oral intake is limited.
• Caution in renal or hepatic impairment: increased risk of prolonged hypoglycemia.
• Pregnancy and lactation: use only if benefits outweigh potential risks and under medical supervision.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Major Interactions (Avoid)

• Concurrent use of other insulins or insulin secretagogues may precipitate severe hypoglycemia.
• Beta‑blockers can mask hypoglycemia symptoms and prolong its duration.
• MAO‑inhibitors may enhance insulin’s glucose‑lowering effect.

Moderate Interactions (Monitor Closely)

• Sulfonylureas increase hypoglycemia risk; dose adjustments may be needed.
• Thiazide diuretics can raise blood glucose, potentially requiring higher insulin doses.
• Corticosteroids induce hyperglycemia, possibly necessitating dose escalation.
• ACE inhibitors may potentiate insulin’s effect on glucose uptake.
• Alcohol intake can cause unpredictable glucose fluctuations.